<DOC>
	<DOCNO>NCT01819766</DOCNO>
	<brief_summary>This study aim determine performance Exact IBD-ACRN surveillance test detect colorectal cancer ( CRC ) colorectal neoplasia patient inflammatory bowel disease ( IBD ) . Patients IBD diagnosis least eight year diagnosis primary sclerosing cholangitis ( PSC ) eligible CRC screen eligible participate study . Enrolled subject collect stool sample Exact IBD-ACRN surveillance test . Subjects must undergo colonoscopy 90 day prior enrollment undergo colonoscopy surgical intervention within 120 day enrollment . Tissue diagnosis CRC establish histopathologic examination .</brief_summary>
	<brief_title>Detection Advanced Colorectal Neoplasia Stool DNA Inflammatory Bowel Disease</brief_title>
	<detailed_description>This prospective , cross sectional , multi-center study determine sensitivity specificity Exact IBD-ACRN surveillance test detect CRC alone combination high grade dysplasia ( HGD ) low grade dysplasia ( LGD ) associate IBD advance adenoma IBD patient disease duration great 8 year PSC diagnosis . Enrolled subject provide single stool sample Exact IBD-ACRN surveillance test , sooner 7 day follow recent pre-enrollment colonoscopy , within 30 day enrollment prior initiate bowel prep either post-enrollment colonoscopy ( surveillance repeat ) , surgical intervention . Stool sample test use Exact IBD-ACRN surveillance test result compare colonoscopy correspond diagnostic histopathology result biopsied , subsequently excise , lesion establish sensitivity specificity Exact IBD-ACRN surveillance test . All post-enrollment colonoscopy surgical intervention must perform within 60 day enrollment . The primary objective study determine sensitivity specificity Exact IBD-ACRN surveillance test CRC IBD patient disease duration least eight year diagnosis PSC . Tissue diagnosis CRC establish histopathology examination . The secondary objective determine sensitivity specificity Exact IBD-ACRN surveillance test detect ACRN IBD patient disease duration least eight year diagnosis PSC . Enrollment continue least 35 CRC ; 15 HGD 315 negative subject sample obtain . There specific recruitment goal IBD associate LGD LGD associate advanced adenoma ( AA ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<criteria>Male female 1884 year age , inclusive . Diagnosis IBD diagnosis PSC IBD prior enrollment date study . Must candidate surveillance colonoscopy , intention CRC/dysplasia surveillance , candidate surgical intervention base prior histological confirmation HGD CRC . Written inform consent document sign date subject legally acceptable representative . Any condition opinion investigator preclude participation study . A history aerodigestive tract cancer . Prior colorectal resection , except ileocolic resection Crohn 's disease patient . IBD limit rectum without concurrent PSC diagnosis . Subject participate clinical study within previous 30 day wherein investigational compound device , may , introduce subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Colorectal Neoplasm</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Primary Sclerosing Cholangitis</keyword>
</DOC>